Serplulimab for Locally Advanced Cervical Cancer

This study is a randomized, controlled, open-label, phase II clinical trial designed to enroll patients with previously untreated locally advanced cervical cancer. The study aims to evaluate the efficacy and safety of adding chemotherapy to serplulimab combined with concurrent chemoradiotherapy. The primary endpoint of this study is progression-free survival (PFS).

NCT Number	NCT07340489
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Cervical Cancer
Enrollment	216 participants
Start Date	2025-12-03
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-14